JP2014517832A - 自己免疫疾患を治療するための方法及び医薬組成物 - Google Patents

自己免疫疾患を治療するための方法及び医薬組成物 Download PDF

Info

Publication number
JP2014517832A
JP2014517832A JP2014509736A JP2014509736A JP2014517832A JP 2014517832 A JP2014517832 A JP 2014517832A JP 2014509736 A JP2014509736 A JP 2014509736A JP 2014509736 A JP2014509736 A JP 2014509736A JP 2014517832 A JP2014517832 A JP 2014517832A
Authority
JP
Japan
Prior art keywords
enolase
seq
polypeptide
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014509736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517832A5 (US20090208454A1-20090820-C00047.png
Inventor
ヴィーテコック，オリヴィエ
ドゥランビュール，セリーヌ
ルケル，ティエリー
ボイエ，オリヴィエ
トロン，フランソワ
ル・ロエ，グザヴィエ
ジルベール，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rouen Normandie
Original Assignee
Universite de Rouen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rouen Normandie filed Critical Universite de Rouen Normandie
Publication of JP2014517832A publication Critical patent/JP2014517832A/ja
Publication of JP2014517832A5 publication Critical patent/JP2014517832A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014509736A 2011-05-10 2012-05-10 自己免疫疾患を治療するための方法及び医薬組成物 Pending JP2014517832A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305557 2011-05-10
EP11305557.8 2011-05-10
PCT/EP2012/058678 WO2012152882A1 (en) 2011-05-10 2012-05-10 Methods and pharmaceutical compositions for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2014517832A true JP2014517832A (ja) 2014-07-24
JP2014517832A5 JP2014517832A5 (US20090208454A1-20090820-C00047.png) 2015-05-28

Family

ID=44653630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509736A Pending JP2014517832A (ja) 2011-05-10 2012-05-10 自己免疫疾患を治療するための方法及び医薬組成物

Country Status (5)

Country Link
US (1) US20140086895A1 (US20090208454A1-20090820-C00047.png)
EP (1) EP2707018B1 (US20090208454A1-20090820-C00047.png)
JP (1) JP2014517832A (US20090208454A1-20090820-C00047.png)
ES (1) ES2560012T3 (US20090208454A1-20090820-C00047.png)
WO (1) WO2012152882A1 (US20090208454A1-20090820-C00047.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment
EA201691420A1 (ru) 2014-01-13 2016-12-30 Берг Ллк Композиции енолазы 1 (eno1) и их применение
CN107847560A (zh) * 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
CA3195040A1 (en) * 2020-10-06 2022-04-14 Matthias W. Hentze Screening method for the identification of novel therapeutic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008090360A1 (en) * 2007-01-25 2008-07-31 Imperial Innovations Limited Methods
WO2010117694A2 (en) * 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929758A (en) 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4102877A (en) 1976-07-28 1978-07-25 Merck & Co., Inc. Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008090360A1 (en) * 2007-01-25 2008-07-31 Imperial Innovations Limited Methods
WO2010117694A2 (en) * 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6016007756; Ａｒｔｈｒｉｔｉｓ　Ｒｅｓ．Ｔｈｅｒ． Ｖｏｌ．１１, 2009, Ｒ３８ *
JPN6016007757; Ａｕｔｏｉｍｍｕｎ．Ｒｅｖ． Ｖｏｌ．６, 2007, ｐ．１７６-１８２ *

Also Published As

Publication number Publication date
EP2707018B1 (en) 2015-11-04
US20140086895A1 (en) 2014-03-27
EP2707018A1 (en) 2014-03-19
ES2560012T3 (es) 2016-02-17
WO2012152882A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
JP6474797B2 (ja) インターロイキン１５（ｉｌ−１５）アンタゴニスト並びに自己免疫疾患及び炎症性疾患の処置のためのその使用
TWI461209B (zh) 包含抗原tau肽之免疫原及其組合物
JP5859150B2 (ja) Ｐｃｓｋ９ワクチン
Zhang et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
AU2019202958B2 (en) Aav-based gene therapy for multiple sclerosis
EP2707018B1 (en) Methods and pharmaceutical compositions for the treatment of autoimmune diseases
EP4205762A1 (en) Improved dna vaccine for sars-cov-2
JP6001974B2 (ja) アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
JP7432851B2 (ja) ヒトキヌレニナーゼ酵素及びその使用
US20200030413A1 (en) Methods and pharmaceutical compositions for the treatment of kidney cancer
JP7236446B2 (ja) コア－シェル構造のマイクロ粒子を有効成分として含む血液凝固因子遺伝子発現増加用組成物
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
CN108977464B (zh) 用于提高B型血友病患者的凝血活性的组合物、药物和sgRNA
US20220090134A1 (en) Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccine
WO2023003826A2 (en) Single- and multi-epitope peptide and mrna vaccines to generate tolerogenic effects for allergic and autoimmune disease by targeting liver sinusoidal endothelial cells
NZ506637A (en) Tumor associated antigen 791tgp72
WO2002030982A2 (en) Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
Zhang et al. Characterization of a Partially Protective B‐cell Epitope within the 62 kDa Antigen of Schistosoma japonicum
KR20180088458A (ko) 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
Landry et al. Mutants of Cocaine Esterase

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150310

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170328